Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-04-24 Regulatory Filings
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - DECHRA PHARMACEUTICALS PLC
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 8.3 - DECHRA PHARMACEUTICALS PLC' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a mandatory disclosure required when a person or entity acquires or disposes of interests in relevant securities of an offeror or offeree during a takeover bid. This specific type of regulatory filing, dealing with insider/significant shareholder transactions during a takeover process, does not fit neatly into the standard categories like 10-K, ER, or IR. It is a specific regulatory disclosure related to insider dealings during a takeover scenario. While 'DIRS' (Director's Dealing) is related to insider transactions, Form 8.3 is specifically tied to the Takeover Code during an active M&A event, making it a specialized regulatory filing. Given the options, 'RNS' (Regulatory Filings - general/fallback) is the most appropriate category for a specific, non-standard regulatory disclosure like a Form 8.3, as it is not a standard periodic report (10-K, IR) or a general management/dividend announcement. It is a mandatory filing with the Takeover Panel.
2023-04-24 English
Form 8.3 - DECHRA PHARMACEUTICALS PLC
M&A Activity Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - DECHRA PHARMACEUTICALS PLC' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure is directly related to ongoing takeover activity, which falls under Merger & Acquisition (M&A) related filings. While the specific form (Form 8.3) is not listed directly, its purpose aligns most closely with the 'M&A Activity' category (TAR), as it reports holdings related to a takeover target (Dechra Pharmaceuticals plc) during a relevant period. It is not an Annual Report (10-K), Earnings Release (ER), or a general regulatory filing (RNS), as it is highly specific to takeover rules.
2023-04-24 English
Form 8.3 - Dechra Pharmaceuticals PLC (DPH LN)
Director's Dealing Classification · 95% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals PLC (DPH LN)' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. Form 8.3 is a mandatory disclosure required under the UK Takeover Code when a person holding interests in 1% or more of the relevant securities of an offeror or offeree engages in dealing activity during an offer period. This specific filing details the 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE' by Grandeur Peak Global Advisors, LLC regarding Dechra Pharmaceuticals PLC. This type of filing relates directly to insider/significant shareholder activity during a takeover scenario, which falls under the scope of Director's Dealing (DIRS) or, more broadly, regulatory filings concerning takeover activity. Since 'DIRS' is defined as 'Report of personal share transactions by company directors and executives (insider trades)', and this is a mandatory disclosure of a significant shareholder's position and dealing during a takeover, it aligns most closely with insider/significant transaction reporting. However, given the specific context of the Takeover Code (Rule 8.3), it is a specialized form of insider dealing disclosure. Comparing the options, 'DIRS' (Director's Dealing) is the closest fit for reporting significant share transactions by an interested party, even if not strictly a director. If a more specific 'Takeover Disclosure' category existed, it would be preferred, but among the provided codes, DIRS captures the essence of reporting significant security interests and transactions by an insider/major holder. Alternatively, as a mandatory regulatory filing related to a takeover, it could be RNS, but DIRS is more specific to the content type (dealing disclosure). I will classify it as DIRS due to the focus on security interests and dealings by a major holder during a corporate action (implied takeover context).
2023-04-20 English
Form 8 (OPD) - Dechra Pharmaceuticals PLC
Director's Dealing Classification · 95% confidence The document is explicitly titled 'FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER' and references 'Rules 8.1 and 8.2 of the Takeover Code (the "Code")'. This form is used to disclose interests and short positions related to a takeover offer, which falls under insider/director dealing or specific regulatory disclosures related to corporate actions. Since the document details shareholdings and options of directors and persons acting in concert during an offer period, it is a specific type of insider transaction disclosure. While 'DIRS' (Director's Dealing) is close, this filing is specifically mandated by the Takeover Code (Rule 8) during an offer, making it a highly specific regulatory disclosure. Given the options, 'DIRS' (Director's Dealing) is the closest fit for reporting executive share transactions, although 'RNS' (Regulatory Filings) is also plausible as a general category. However, the content is fundamentally about director/insider positions during an offer, which aligns best with the intent of DIRS, even if the specific form is 'Form 8 (OPD)'. Since the definitions do not explicitly list a 'Takeover Disclosure' code, and this involves director/insider positions, DIRS is the most appropriate specific classification over the general RNS fallback.
2023-04-20 English
Form 8.3 - Dechra Pharmaceuticals PLC
M&A Activity Classification · 95% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals PLC" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a Public Opening Position Disclosure or Dealing Disclosure made by a person holding 1% or more interest in relevant securities during a takeover situation. This type of filing relates to insider transactions or significant ownership changes during a takeover bid, which falls under the scope of regulatory disclosures concerning corporate actions, specifically takeovers. While it involves director/insider activity (similar to DIRS), the specific context of Rule 8.3 of the Takeover Code makes it a specialized regulatory filing related to M&A activity. However, none of the provided codes perfectly match a 'Takeover Disclosure Form 8.3'. Let's evaluate the closest fits: 1. DIRS (Director's Dealing): This is related to insider trades, but Form 8.3 is specific to takeover rules, not general insider reporting. 2. TAR (M&A Activity): This is the most relevant thematic category as Form 8.3 is triggered by a takeover offer. 3. RNS (Regulatory Filings): This is the general fallback for miscellaneous regulatory filings. Given that the document is a mandatory disclosure under the UK Takeover Code concerning interests in securities during an offer, it is fundamentally an M&A-related regulatory filing. Therefore, TAR (M&A Activity) is the most appropriate specific classification, as it directly relates to the context (a takeover offer for Dechra Pharmaceuticals PLC). If TAR is too broad, RNS would be the fallback. Since the document details positions and dealings directly related to an ongoing takeover scenario (implied by the reference to the Takeover Code), TAR is selected as the best fit over the generic RNS.
2023-04-20 English
Form 8.3 - Dechra Pharmaceuticals PLC
Director's Dealing Classification · 95% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals PLC' and references 'Rule 8.3 of the Takeover Code'. This form is a mandatory disclosure required when a person or entity holds interests of 1% or more in the relevant securities of an offeror or offeree during a takeover bid. This type of filing relates to insider dealings or significant ownership changes during a takeover scenario. Among the provided codes, 'Director's Dealing' (DIRS) covers personal share transactions by executives, and while this is a dealing disclosure, the context is specifically a takeover bid disclosure (Form 8.3). However, 'Director's Dealing' (DIRS) is the closest fit for reporting personal/insider security transactions, even though the specific regulatory context is a takeover. Given the options, DIRS is the most appropriate category for reporting security interests/dealings by an interested party, which is the core function of Form 8.3, although it is not strictly limited to directors. If a more specific 'Takeover Disclosure' code existed, it would be preferred. Since it involves reporting security interests and dealings by an interested party, DIRS is selected as the best fit among the available choices.
2023-04-19 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.